Market research
RDDA.F Dr. Reddy's Laboratories Limited
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8B
- P/E ratio
- 27.5
- Analyst target
- 77.85
- Dividend yield
- 78.%
- Beta
- 0.24
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US2561352038
- Market cap
- 8B
- P/E ratio
- 27.5
- Analyst target
- 77.85
- Dividend yield
- 78.%
- Beta
- 0.24
About
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RDDA.F discussion.
5 years, 5 months ago
Dr. Reddy's Laboratories Limited is currently in a long term uptrend where the price is trading 11.9% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.1.
Dr. Reddy's Laboratories Limited's total revenue rose by 12.5% to $49B since the same quarter in the previous year.
Its net income has increased by 103.5% to $198M since the same quarter in the previous year.
Finally, its free cash flow fell by 76.5% to $1B since the same quarter in the previous year.
Based on the above factors, Dr. Reddy's Laboratories Limited gets an overall score of 4/5.